Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

SOHO 2025 | CAR-T and bispecific antibodies: reshaping relapsed/refractory myeloma care

Hans Lee • 4 Sep 2025
SOHO 2025
Multiple Myeloma Antibodies CAR-T

In this video, Hans Lee, MD, Sarah Cannon Research Institute, Nashville, TN, discusses significant changes in the treatment of relapsed/refractory multiple myeloma, highlighting the impact of T-cell redirecting therapies such as bispecific antibodies and CAR T-cells. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Hans Lee

The growing role of quadruplet-based regimens in newly diagnosed multiple myeloma 1:09
The growing role of quadruplet-based regimens in newly diagnosed multiple myeloma
Hans Lee • 4 Sep 2025
A MAIC of linvoseltamab versus ide-cel and cilta-cel in triple-class-exposed RRMM 2:25
A MAIC of linvoseltamab versus ide-cel and cilta-cel in triple-class-exposed RRMM
Hans Lee • 19 Sep 2025
Long-term follow-up and subgroup analyses from the LINKER-MM1 trial of linvoseltamab in myeloma 2:44
Long-term follow-up and subgroup analyses from the LINKER-MM1 trial of linvoseltamab in myeloma
Hans Lee • 19 Sep 2025
First-in-human Phase I study of JNJ-5322, a novel trispecific antibody, in R/R myeloma 3:09
First-in-human Phase I study of JNJ-5322, a novel trispecific antibody, in R/R myeloma
Hans Lee • 4 Sep 2025

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals